Abstract

Lassa virus infects hundreds of thousands of people each year across rural West Africa, resulting in a high number of cases of Lassa fever (LF), a febrile disease associated with high morbidity and significant mortality. The lack of approved treatments or interventions underscores the need for an effective vaccine. At least four viral lineages circulate in defined regions throughout West Africa with substantial interlineage nucleotide and amino acid diversity. An effective vaccine should be designed to elicit Lassa virus specific humoral and cell mediated immunity across all lineages. Most current vaccine candidates use only lineage IV antigens encoded by Lassa viruses circulating around Sierra Leone, Liberia, and Guinea but not Nigeria where lineages I-III are found. As previous infection is known to protect against disease from subsequent exposure, we sought to determine whether LF survivors from Nigeria and Sierra Leone harbor memory T cells that respond to lineage IV antigens. Our results indicate a high degree of cross-reactivity of CD8+ T cells from Nigerian LF survivors to lineage IV antigens. In addition, we identified regions within the Lassa virus glycoprotein complex and nucleoprotein that contributed to these responses while T cell epitopes were not widely conserved across our study group. These data are important for current efforts to design effective and efficient vaccine candidates that can elicit protective immunity across all Lassa virus lineages.

Highlights

  • Lassa virus (LASV) infects hundreds of thousands of individuals each year in West Africa, resulting in thousands of Lassa fever (LF) cases with a high case fatality rate among hospitalized individuals with severe LF symptoms

  • A vaccine effective against the four main lineages of LASV is needed to protect susceptible individuals across West Africa. To understand how this protection could occur, we examined the immune responses of LF survivors from two different regions of West Africa

  • As previous infection with Lassa virus protects from disease after subsequent exposure, the immune response of LF survivors provides a model of protective immunity that could be induced after vaccination

Read more

Summary

Introduction

Lassa virus (LASV) infects hundreds of thousands of individuals each year in West Africa, resulting in thousands of LF cases with a high case fatality rate among hospitalized individuals with severe LF symptoms. The lack of any approved interventions or vaccines make LASV a serious threat to the general public and to health care workers treating Lassa fever patients. There are at least four distinct LASV lineages circulating in West Africa[1, 6,7,8]. Though these lineages circulate in geographically distinct regions, an effective vaccine should ideally protect against strains from all LASV lineages. Some, but not all, LASV-specific CD4+ T cells from lineage IV infected LF survivors responded to antigens from lineage III[11]

Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call